The Ontario Institute for Cancer Research (OICR) has announced its support for five Ontario research teams working to develop the next generation of medicines that kill tumours more effectively, cause ...

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

IRBM is a contract research organization (CRO) focused on early-stage drug discovery. With a track record of delivering preclinical candidates across oncology, neurodegeneration, and infectious ...

Developing new drugs to treat illnesses has typically been a slow and expensive process. However, a team of researchers at ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

An international team led by Rutgers University-New Brunswick researchers has merged two lab-synthesized materials into a ...

Ethan Grimes, BS, and Paul Morgan, MD, conduct rational drug design at the newly launched AI Small Molecule Drug Discovery Center at the Icahn School of Medicine at Mount Sinai. As part of Mount Sinai ...

The AI Small Molecule Drug Discovery Center will focus on three core areas: designing novel drug-like molecules using generative AI, optimizing existing compounds to enhance their efficacy and safety, ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Causaly today announced new scientific AI agents that provide research teams with the industry's most comprehensive ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Pickup pulled over due to the “Eagles” border frame blocking license plate, then a firearm and marijuana were found, police ...